Background on Semaglutide and Compounding Pharmacies Semaglutide, a GLP-1 receptor agonist, is widely used for type 2 diabetes and weight loss under brand names like Ozempic and Wegovy
The estimated mean change in body weight at week 68 was 20.4% with CagriSema versus 3.0% with placebo (a difference of about 17 percentage points), and more CagriSema participants reached weight-loss thresholds of 5%, 20%, 25%, and 30% than placebo
Rapidbac can be applied at the same time as Muck Remover, Phosphate Eliminator or Pond Dye
Its main weaknesses are pricing transparency and pharmacy disclosure, not its legitimacy or medication handling
Thomas MK, Nikooienejad A, Bray R et al (2021) Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes